Last updated: 23 July 2019 at 12:04am EST

Clarence L Dellio Net Worth




The estimated Net Worth of Clarence L Dellio is at least $2.92 Milion dollars as of 11 May 2005. Clarence Dellio owns over 10,974 units of XOMA Royalty stock worth over $2,751,487 and over the last 21 years Clarence sold XOMA stock worth over $164,859.

Clarence Dellio XOMA stock SEC Form 4 insiders trading

Clarence has made over 5 trades of the XOMA Royalty stock since 2004, according to the Form 4 filled with the SEC. Most recently Clarence sold 10,974 units of XOMA stock worth $15,473 on 11 May 2005.

The largest trade Clarence's ever made was exercising 23,969 units of XOMA Royalty stock on 2 January 2004 worth over $61,361. On average, Clarence trades about 5,921 units every 49 days since 2003. As of 11 May 2005 Clarence still owns at least 101,456 units of XOMA Royalty stock.

You can see the complete history of Clarence Dellio stock trades at the bottom of the page.



What's Clarence Dellio's mailing address?

Clarence's mailing address filed with the SEC is , , , , .

Insiders trading at XOMA Royalty

Over the last 21 years, insiders at XOMA Royalty have traded over $74,428,857 worth of XOMA Royalty stock and bought 6,217,869 units worth $44,091,555 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... oraz Bros. Advisors Lp667, L.P.B.... On average, XOMA Royalty executives and independent directors trade stock every 31 days with the average trade being worth of $3,397,377. The most recent stock trade was executed by Owen Hughes on 2 October 2023, trading 1,000 units of XOMA stock currently worth $13,830.



What does XOMA Royalty do?

xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.



What does XOMA Royalty's logo look like?

XOMA Royalty Corp. logo

Complete history of Clarence Dellio stock trades at XOMA Royalty

Data
#
Firma
Osoba
Trans.
Transakcja
Ilość akcji Cena za akcję Łączna cena Ilość akcji po Źródło
11 May 2005 Clarence L Dellio
Sr VP, Operacje oraz COO
Sprzedaż 10,974 $1.41 $15,473
11 May 2005
101,456
20 Sep 2004 Clarence L Dellio
Sr VP, Operacje oraz COO
Sprzedaż 4,294 $2.51 $10,778
20 Sep 2004
98,677
30 Jun 2004 Clarence L Dellio
Sr VP, Operacje oraz COO
Sprzedaż 4,000 $4.75 $19,000
30 Jun 2004
102,971
12 Jan 2004 Clarence L Dellio
Sr VP, Operacje oraz COO
Sprzedaż 15,969 $7.49 $119,608
12 Jan 2004
101,236
2 Jan 2004 Clarence L Dellio
Sr VP, Operacje oraz COO
Opcja Ćwiczenie 23,969 $2.56 $61,361
2 Jan 2004
117,205


XOMA Royalty executives and stock owners

XOMA Royalty executives and other stock owners filed with the SEC include: